AbbVie Bolsters Immunology Pipeline with $10.9 Billion Apogee Acquisition
The acquisition would add a longer-acting alternative to Dupixent for inflammatory diseases.
The acquisition would add a longer-acting alternative to Dupixent for inflammatory diseases.
Jefferies initiates Buy on Design Therapeutics ($15 PT) & assumes coverage on Revolution Medicines ($140), Kymera ($110), Immatics ($18), Insmed ($228).
Kymera Therapeutics (KYMR) shares surge after Phase 1b trial shows KT-621 oral pill achieves Dupixent-like efficacy in treating moderate to severe eczema with favorable safety profile.